Your session is about to expire
Methotrexate vs Sulfasalazine
Introduction
For patients with rheumatoid arthritis or psoriatic arthritis, certain drugs that inhibit the progression of these diseases by mitigating inflammation can help in managing symptoms and enhancing quality of life. Methotrexate and Sulfasalazine are two such drugs that are commonly prescribed for these conditions. They each have different mechanisms of action, but both effectively reduce inflammation in patients with arthritis. Methotrexate is a disease-modifying anti-rheumatic drug (DMARD), which works by suppressing the immune system to reduce inflammation and slow down disease progression. On the other hand, Sulfasalazine is classified as an aminosalicylate used to treat inflammatory bowel diseases primarily but also has significant effects on reducing inflammation in joints when treating rheumatoid or psoriatic arthritis.
Methotrexate vs Sulfasalazine Side By Side
| Attribute | Rheumatrex trexall | Azulfidine |
|---|---|---|
| Brand Name | Rheumatrex, Trexall | Azulfidine |
| Contraindications | Active bacterial infections, peptic ulcers, ulcerative colitis, alcohol abuse history, compromised immunity (e.g., HIV/AIDS) | Intestinal or urinary obstruction, porphyria, allergy to sulfa drugs |
| Cost | Approximately $0.25/day to $3.33/day depending on dosage and quantity purchased | Approximately $0.90–$1/dose to $2.50 - $5/day depending on dosage and quantity purchased |
| Generic Name | Methotrexate | Sulfasalazine |
| Most Serious Side Effect | Liver toxicity, lung problems | Severe skin reaction, liver problems |
| Severe Drug Interactions | Liver-damaging drugs | Not specifically mentioned, but caution advised with other medications due to potential for increased side effects |
| Typical Dose | 7.5 mg to 25 mg once a week | 500 mg per day initially, gradually increasing to 2,000 to 3,000 mg per day divided into two doses |
What is Methotrexate?
Methotrexate, which was first approved by the FDA in 1953, is part of a class of drugs known as antimetabolites that inhibit cell growth and reproduction. It has been widely used for treatment of severe rheumatoid arthritis when other treatments have failed or aren't suitable. Methotrexate works by suppressing the body's immune system and slowing down the growth of skin cells. On the other hand, Sulfasalazine belongs to a class of anti-inflammatory drugs called disease-modifying antirheumatic drugs (DMARDs) and it functions by reducing inflammation within joints thus relieving pain and swelling associated with rheumatoid arthritis. Originally used for treating inflammatory bowel diseases like ulcerative colitis, Sulfasalazine was later found beneficial in managing rheumatoid arthritis symptoms too. Both these medications can be effective but they come with their own set potential side effects. However, Methotrexate tends to have stronger effects on the overall immune system compared to Sulfasalazine.
What conditions is Methotrexate approved to treat?
Methotrexate is cleared for use in managing a variety of conditions including:
- Rheumatoid arthritis, a chronic inflammatory disorder affecting the small joints
- Psoriasis, a skin condition that causes skin cells to multiply up to 10 times faster than normal
- Certain types of cancer such as acute lymphoblastic leukemia and breast cancer.
How does Methotrexate help with these illnesses?
Methotrexate assists in managing autoimmune conditions like rheumatoid arthritis by decreasing the activity of the immune system. It achieves this by inhibiting an enzyme called dihydrofolate reductase, which plays a crucial role in the production of DNA and RNA, thus slowing down cell growth and division. This is particularly useful in managing diseases marked by rapid cell growth or overactive immune responses. In contrast to neurotransmitters such as serotonin that influence mood and cognition, these cellular mechanisms are central to inflammation, tissue damage, and other symptoms typical for many autoimmune disorders.
Sulfasalazine also aims at reducing inflammation but does so through a different mechanism. After ingestion, it gets broken down into sulfapyridine and 5-aminosalicylic acid (5-ASA) in your gut. The latter is considered to be the main active component responsible for its anti-inflammatory effects although the exact way it works remains unclear.
Both drugs can help manage symptoms of specific chronic conditions but their effectiveness may vary from individual to individual due to genetics, condition severity or presence of other health issues.
What is Sulfasalazine?
Sulfasalazine is a disease-modifying antirheumatic drug (DMARD) traditionally used in the treatment of inflammatory bowel diseases, rheumatoid arthritis and psoriatic arthritis. Unlike methotrexate, which works by inhibiting an enzyme involved in the rapid growth of cells, sulfasalazine acts primarily by reducing inflammation and suppressing the immune system. Sulfasalazine was first approved by the FDA in 1950 and it's often administered orally, typically as a delayed-release tablet to minimize gastrointestinal side effects.
As sulfasalazine does not inhibit cell growth directly like methotrexate, its side-effect profile differs - particularly its lower risk for liver toxicity or lung problems that can occur with methotrexate use. Common side effects may include nausea, vomiting or mild stomach discomfort alongside headache or dizziness. Its anti-inflammatory action can be beneficial especially for patients who don't respond well to other treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids or even other DMARDs including Methotrexate.
What conditions is Sulfasalazine approved to treat?
Sulfasalazine is an FDA-approved medication for the management of:
- Rheumatoid arthritis
- Ulcerative colitis, which is a type of inflammatory bowel disease
- Other conditions where inflammation plays a key role like psoriatic arthritis and ankylosing spondylitis
How does Sulfasalazine help with these illnesses?
Sulfasalazine is a type of drug known as a disease-modifying anti-rheumatic drug (DMARD). It works by reducing inflammation in the body, and is thus used to treat conditions such as rheumatoid arthritis and inflammatory bowel disease. Sulfasalazine accomplishes this by releasing 5-aminosalicylic acid and sulfapyridine into the colon where it suppresses inflammation. Compared to Methotrexate, another DMARD which inhibits metabolism of folic acid, Sulfasalazine may cause lesser side effects like nausea or mouth sores. However, its efficacy can be lower than that of methotrexate for certain patients. Therefore, it might be considered when a patient does not respond well to other DMARDs like Methotrexate or could be combined with them for an enhanced therapeutic effect.
How effective are both Methotrexate and Sulfasalazine?
Both methotrexate and sulfasalazine have established histories of success in managing rheumatoid arthritis, and they were initially approved by the FDA several years apart. Since they act on different pathways to reduce inflammation, they may be prescribed under different circumstances. The effectiveness of methotrexate and sulfasalazine was directly studied in a double-blind clinical trial in 1999; the two drugs exhibited similar efficacy in managing symptoms of rheumatoid arthritis as well as similar safety profiles. In this study, none of the different metrics studied to measure efficacy differed between patients receiving methotrexate or those receiving sulfasalazine.
A 2005 review reported that methotrexate is effective from the early weeks of treatment, has an acceptable side effect profile compared with other disease-modifying antirheumatic drugs (DMARDs), and that it is well-tolerated even among older populations with comorbidities. Methotrexate has become one of the most commonly prescribed DMARDs worldwide due to its effectiveness at reducing joint damage and preserving function over time.
A 2017 review indicated that sulfasalazine seems to be more effective than placebo for treating mild-to-moderate cases of rheumatoid arthritis, but it might not be quite as effective as other common DMARDs such as methotrexate or leflunomide. Nonetheless, when used alongside another DMARD like hydroxychloroquine or methotrexate ("triple therapy"), it can yield significant benefits without dramatically increasing toxicity risk.
Related trials for methotrexate and sulfasalazine
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Methotrexate typically prescribed?
Oral dosages of Methotrexate for rheumatoid arthritis usually start from 7.5 mg once a week, but some studies have indicated that up to 25 mg/week can be used depending on the severity of disease and patient tolerance. For children with juvenile idiopathic arthritis, the dosage may vary between 10–15mg/m2 per week. In either population, dosage can be adjusted after a few weeks based on response and side effects. The maximum weekly dose should not exceed 30mg.
On the other hand, Sulfasalazine is typically started at lower doses such as 500mg/day in adults then gradually increased over several weeks to reduce gastrointestinal upset; an effective therapeutic dose often falls within the range of 2000 -3000 mg/day divided into two doses for treating rheumatoid arthritis. Children’s dosage is calculated by body weight at approximately 40-60mg/kg per day split into two doses.
At what dose is Sulfasalazine typically prescribed?
Sulfasalazine treatment is typically started at a lower dosage of 500 mg per day. This dose can be gradually increased by 500 mg every week until reaching a daily dosage ranging from 2,000 to 3,000 mg, divided into two doses and spaced approximately 12 hours apart. The maximum dose reaches up to four grams per day (4,000 mg), divided into several doses throughout the day and taken after meals. If there's no sufficient response or improvement in symptoms after a few weeks of reaching the desired dose, your healthcare provider may consider further adjustments or additional therapies.
What are the most common side effects for Methotrexate?
While both Methotrexate and Sulfasalazine are used to treat rheumatoid arthritis, their side effects can differ. Common side effects of methotrexate may include:
- Nausea or vomiting
- Dizziness or drowsiness
- Temporary hair loss
- Anemia (low red blood cell count)
- Skin rash or itching
- Increased sensitivity to sunlight
On the other hand, sulfasalazine may cause:
- Mild stomach pain or discomfort
- Headache
- Rash, itching, hives
- Decreased sperm count in men (which is reversible upon stopping the medication) Remember that these lists do not include all possible side effects. If you notice any unusual symptoms while taking either drug, it's important to contact your healthcare provider immediately.
Are there any potential serious side effects for Methotrexate?
While both Methotrexate and Sulfasalazine are widely used for the treatment of rheumatoid arthritis, they have different side effects. In rare cases, Methotrexate can cause serious side effects such as:
- Signs of lung problems like shortness of breath or difficulty breathing
- Yellowing skin or eyes (jaundice), dark urine, persistent nausea/vomiting due to liver issues.
- Unusual bleeding or bruising
- Severe fatigue
- Mouth sores
Sulfasalazine on the other hand might cause different symptoms including:
- Skin rash, itching or hives; these could be signs of an allergic reaction
- Fever
- Painful urination and changes in urine color to orange-yellow Severe headaches and dizziness Stiff neck accompanied by sensitivity to light indicating potential meningitis.
Always remember that you should contact your healthcare provider immediately if you experience any unusual symptoms after taking either medication.
What are the most common side effects for Sulfasalazine?
With Sulfasalazine, some users might experience:
- Dry mouth or changes in taste
- Stomach upset, nausea, vomiting and loss of appetite
- Mild rash and itching
- Headache or dizziness
- Temporary hair loss
- Sensitivity to sunlight causing skin rash, itching, redness or other discoloration of the skin
- Orange-yellow discoloration of the urine or skin
- Ringing in the ears It is important to note that these side effects usually lessen over time as your body gets used to the medication. Always consult with a healthcare provider for any concerns about side effects.
Are there any potential serious side effects for Sulfasalazine?
While Sulfasalazine is typically well-tolerated, serious side effects can occur. These include:
- A severe skin reaction that causes a rash, often with blistering or peeling, and possibly accompanied by fever
- Signs of liver problems such as yellowing eyes or skin (jaundice), dark urine, extreme tiredness
- Unusual bleeding or bruising
- Severe nausea, vomiting and abdominal pain
- Kidney problems manifesting as changes in the amount of urine
- Allergic reactions including itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
If you experience any of these symptoms while taking Sulfasalazine, it's crucial to contact your healthcare provider immediately.
Contraindications for Methotrexate and Sulfasalazine?
Just like Wellbutrin and Prozac, methotrexate and sulfasalazine may worsen certain conditions in some people. If you notice any severe side effects or worsening of symptoms while on these medications, please seek immediate medical attention.
Neither methotrexate nor sulfasalazine should be taken if you are currently using or have recently used liver-damaging drugs. Always inform your physician about all the medications you are taking; such substances will require a certain period to clear from the system to prevent potentially harmful interactions with methotrexate and sulfasalazine.
Both drugs can cause serious lung problems, including acute or chronic interstitial pneumonitis that can lead to severe shortness of breath; contact your healthcare provider immediately if you experience this symptom. Methotrexate specifically is not recommended for patients with active bacterial infections, peptic ulcers, ulcerative colitis, alcohol abuse history or compromised immunity due to other diseases like HIV/AIDS.
Sulfasalazine is contraindicated in individuals with intestinal or urinary obstruction and those with porphyria as it may precipitate an attack. It's also important that anyone allergic to sulfa drugs avoid taking sulfasalazine.
How much do Methotrexate and Sulfasalazine cost?
For the brand name versions of these drugs:
- The price for 60 tablets of Rheumatrex, a brand-name methotrexate (2.5 mg), averages around $100-$200, which works out to about $1.67 - $3.33/day depending on your dose.
- Conversely, the price for 120 tablets of Azulfidine, a branded version of sulfasalazine (500 mg), costs around $300-$600; this equates to approximately $2.50 - $5/day.
Hence if you are in the higher dosage range for methotrexate (i.e., 20 mg/week or more), then sulfasalazine could be less expensive on a per-day treatment basis. However, cost should not be a primary consideration in determining which drug is right for you: efficacy and side effects must also be taken into account.
Regarding generic versions – prices are significantly lower:
- Methotrexate can come in packs ranging from 24 up to 100 tablets (2.5mg) with costs starting as low as about $.25/day when buying larger quantities upfront.
- Sulfasalazine is available in packs from 60 up to several hundred (500mg); even when taking typical dosages of between one and three grams per day, costs often do not exceed about $.90–$1/dose if large amounts are purchased at once.
Popularity of Methotrexate and Sulfasalazine
Methotrexate, both in generic form and under brand names such as Rheumatrex and Trexall, is a commonly prescribed medication for rheumatoid arthritis. It was estimated to have been prescribed to about 1 million people in the US in 2020. Methotrexate accounted for just over 40% of disease-modifying antirheumatic drug (DMARD) prescriptions in the US, making it the most common conventional DMARD used. Methotrexate has been generally increasing in prevalence since its approval by FDA.
Sulfasalazine, including brand versions such as Azulfidine, is another medication used for rheumatoid arthritis as well as other inflammatory diseases like ulcerative colitis and Crohn's Disease. Sulfasalazine was prescribed to approximately half a million people in the USA during 2020. In terms of overall DMARD prescriptions, sulfasalazine accounts for about 10%. Despite newer drugs coming on market with more specific targets and potentially less side effects like biologic DMARDS , sulfasalazine has remained relatively steady over the last decade due to its cost-effectiveness.
Conclusion
Both Methotrexate and Sulfasalazine are commonly used in the management of rheumatoid arthritis, and their efficacy is backed by a multitude of clinical trials illustrating their superiority over placebo treatments. At times, these drugs might be used in combination but this decision should be made carefully by a physician as there could be potential contraindications. This stems from their different modes of action; methotrexate inhibits an enzyme involved in DNA synthesis, while sulfasalazine acts primarily as an anti-inflammatory agent.
Methotrexate is often the first-line treatment option for patients with moderate to severe rheumatoid arthritis or those who do not respond well to nonsteroidal anti-inflammatory drugs (NSAIDs) or disease-modifying antirheumatic drugs (DMARDs). On the other hand, sulfasalazine may serve as an adjunctive therapy to methotrexate or for patients who need to avoid certain side effects associated with methotrexate such as liver toxicity and lung issues.
Both medications are available in generic form which can make them more affordable especially for individuals without insurance coverage. Adjustments may also need to be made during the initial stages of treatment since beneficial effects might not become apparent immediately.
In terms of side effect profiles, both medications have comparable tolerability however they each carry unique risks. Methotrexate can cause serious liver toxicity and lung problems whereas sulfasalazine may result in gastrointestinal upset and skin rashes among others. Patients taking either medication must closely monitor their symptoms particularly at the beginning phase of therapy and seek immediate medical attention if any adverse reactions occur.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Dale, J., Alcorn, N., Capell, H., & Madhok, R. (2007, August). Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nature Clinical Practice Rheumatology. Springer Science and Business Media LLC.http://doi.org/10.1038/ncprheum0562
- O'Dell, J. R., Haire, C. E., Erikson, N., Drymalski, W., Palmer, W., Eckhoff, P. J., … Moore, G. F. (1996, May 16). Treatment of Rheumatoid Arthritis with Methotrexate Alone, Sulfasalazine and Hydroxychloroquine, or a Combination of All Three Medications. New England Journal of Medicine. Massachusetts Medical Society.http://doi.org/10.1056/nejm199605163342002
- Plosker, G. L., & Croom, K. F. (2005). Sulfasalazine. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/00003495-200565130-00008
- Rains, C. P., Noble, S., & Faulds, D. (1995, July). Sulfasalazine. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/00003495-199550010-00009
- Visser, K., & van der Heijde, D. (2008, November 25). Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Annals of the Rheumatic Diseases. BMJ.http://doi.org/10.1136/ard.2008.092668
- Gran, J. T., & Myklebust, G. (1993, January). Toxicity of Sulphasalazine in Rheumatoid Arthritis. Possible Protective Effect of Rheumatoid Factors and Corticosteroids. Scandinavian Journal of Rheumatology. Informa UK Limited.http://doi.org/10.3109/03009749309095128
- Bolla, G., Disdier, P., Harle, J. R., Verrot, D., & Weiller, P. J. (1993, December). Concurrent acute megaloblastic anaemia and pneumonitis : A severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis. Clinical Rheumatology. Springer Science and Business Media LLC.http://doi.org/10.1007/bf02231787
- Moseley, R. H., Barwick, K. W., Dobuler, K., & DeLuca, V. A., Jr. (1985, September). Sulfasalazine-induced pulmonary disease. Digestive Diseases and Sciences. Springer Science and Business Media LLC.http://doi.org/10.1007/bf01309523
- Cipriani, P., Ruscitti, P., Carubbi, F., Liakouli, V., & Giacomelli, R. (2014, September 22). Methotrexate: an old new drug in autoimmune disease. Expert Review of Clinical Immunology. Informa UK Limited.http://doi.org/10.1586/1744666x.2014.962996